Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 0.29 4.77% 0.01
SYRS closed up 4.77 percent on Wednesday, November 20, 2024, on 1.66 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup 4.77%
Volume Surge Other 4.77%
Calm After Storm Range Contraction 4.77%
Narrow Range Bar Range Contraction 4.77%
Lower Bollinger Band Walk Weakness 4.77%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 18 hours ago
Down 5% about 22 hours ago
Down 10% about 22 hours ago
2x Volume Pace about 22 hours ago
1.5x Volume Pace about 22 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Syros Pharmaceuticals, Inc. Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia

Is SYRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.17
52 Week Low 0.183
Average Volume 9,690,425
200-Day Moving Average 4.38
50-Day Moving Average 1.91
20-Day Moving Average 1.81
10-Day Moving Average 1.28
Average True Range 0.34
RSI (14) 29.08
ADX 31.31
+DI 23.86
-DI 42.75
Chandelier Exit (Long, 3 ATRs) 2.37
Chandelier Exit (Short, 3 ATRs) 1.21
Upper Bollinger Bands 3.88
Lower Bollinger Band -0.26
Percent B (%b) 0.13
BandWidth 228.65
MACD Line -0.49
MACD Signal Line -0.23
MACD Histogram -0.2614
Fundamentals Value
Market Cap 7.54 Million
Num Shares 26 Million
EPS 0.85
Price-to-Earnings (P/E) Ratio 0.34
Price-to-Sales 20.62
Price-to-Book 5.06
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.37
Resistance 3 (R3) 0.36 0.33 0.35
Resistance 2 (R2) 0.33 0.31 0.33 0.35
Resistance 1 (R1) 0.31 0.30 0.32 0.32 0.35
Pivot Point 0.28 0.28 0.28 0.28 0.28
Support 1 (S1) 0.26 0.26 0.26 0.26 0.23
Support 2 (S2) 0.23 0.25 0.23 0.23
Support 3 (S3) 0.21 0.23 0.23
Support 4 (S4) 0.21